An observational study in Cancer, sponsored by Centro di Riferimento Oncologico - Aviano. Recruiting at 1 site in Italy. Open to participants aged 13 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-04-14.
Sponsored by Centro di Riferimento Oncologico - Aviano · Observational
This research project builds on a long-standing tradition within our Institute of documenting "free thoughts" and personal reflections shared by adolescent oncology patients and their families. These narratives, collected through "logbooks" in ward rooms and during dedicated events-including those focused on the COVID-19 pandemic-represent a profound tool for patients to reclaim their identity beyond their diagnosis.
The aim is to stimulate and collect patient narratives to better understand their emotional and lived experiences. By analyzing these spontaneous writings, the study aims to improve clinical practice, enhance the patient-provider relationship, and optimize the overall healthcare organization.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's planned enrollment of 500 is above the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Centro di Riferimento Oncologico - Aviano is the lead sponsor of 51 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Adolescents and young adults treated for cancer at the Area giovani CRO from 2021
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Thematic Analysis of Patient Narratives
Evaluation of narrative content to identify key themes, semantic fields (values, emotions, perceptions), and prevailing cultural orientations. The analysis aims to characterize the patient's experience and identify potential unresolved conflicts related to the oncological journey, as defined by Pinardi and De Angelis (2006) methodology.
Time frame: 10 years
Structural Analysis of the text
To identify and examine the core elements of the text, including the narrator, characters, spatial and temporal settings, and point of view.
Time frame: 10 years
Stylistic Analysis
Evaluation of the linguistic register and the identification of key rhetorical figures used to convey personal meaning
Time frame: 10 years
Processual Analysis
ased on the "Processual Analysis" framework (Turchi, 2007), this phase describes the architecture of the text starting from the discursive processes (repertoires) employed by the narrators. The goal is to identify how specific uses of language generate and define the participants' configurations of reality. All the analyses are qualitative
Time frame: 10 years
Started Sep 2021 (actual). Primary completion is estimated for Dec 2027, 75 months after the start.
Of 1,098 non-industry observational studies under Neoplasms, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 227. This study's planned 75 months is above that.
Counting every sponsor, half of 1,246 studies reached it within 58 months; a quarter within 24 and three quarters within 210.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centro di Riferimento Oncologico - Aviano